Filana Therapeutics, Inc.
FLNA
$1.42
-$0.01-0.70%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -66.75% | -81.23% | -77.63% | -66.34% | -15.81% |
| Gross Profit | 66.75% | 81.23% | 77.63% | 66.34% | 15.81% |
| SG&A Expenses | -16.36% | -36.37% | -43.72% | -82.74% | 18.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -48.26% | -67.61% | -62.61% | -79.03% | -5.88% |
| Operating Income | 48.26% | 67.61% | 62.61% | 79.03% | 5.88% |
| Income Before Tax | 55.86% | 54.56% | 61.32% | -818.51% | -193.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 55.86% | 54.56% | 61.32% | -818.51% | -193.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.86% | 54.56% | 61.32% | -818.51% | -193.45% |
| EBIT | 48.26% | 67.61% | 62.61% | 79.03% | 5.88% |
| EBITDA | 48.87% | 68.57% | 62.72% | 79.26% | 5.56% |
| EPS Basic | 46.46% | 54.76% | 61.59% | -787.31% | -183.26% |
| Normalized Basic EPS | -- | 69.19% | 63.05% | -3,583.33% | -182.46% |
| EPS Diluted | 46.36% | 54.67% | 61.59% | -807.69% | -14.07% |
| Normalized Diluted EPS | -- | 69.19% | 63.05% | -3,583.33% | -184.57% |
| Average Basic Shares Outstanding | -- | 0.43% | 0.69% | 4.56% | 12.23% |
| Average Diluted Shares Outstanding | 0.10% | 0.43% | 0.69% | 4.56% | 9.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |